ProfileGDS5678 / 1457337_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 37% 39% 35% 39% 38% 37% 35% 36% 38% 35% 36% 37% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9084338
GSM967853U87-EV human glioblastoma xenograft - Control 22.8425237
GSM967854U87-EV human glioblastoma xenograft - Control 32.9015139
GSM967855U87-EV human glioblastoma xenograft - Control 42.7522935
GSM967856U87-EV human glioblastoma xenograft - Control 52.8419939
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9518638
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8987737
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7949835
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7909236
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8439938
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7951335
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7850936
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8438937
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8337737